ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...
FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...
With the advent of commercial spaceflight, an increasing number of people may be heading into space in the coming years. Some ...
Pregnancy and breastfeeding induces the accumulation of specialized immune cells that reduce the chances of breast cancer ...
A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...
Talha Burki speaks with Fred Ramsdell, Mary Brunkow, and Shimon Sakaguchi about their Nobel-winning discoveries in peripheral immune tolerance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback